Meningiomas: Sex-specific differences and prognostic implications of a chromosome X loss
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noae239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Natalie Berghaus und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms, Chromosomes, Human, X, Biomarkers, Tumor. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Meningiomas are the most common primary intracranial tumors in adults. Several studies proposed new stratification systems with a more accurate risk prediction than the WHO grading, eg, based on methylation and copy-number variations (CNVs). Yet, common shortcomings in these analyses are either a lack of stratification by sex of patients or excluding the gonosomes from CNV assessment.
Methods
Within this study, DNA methylation array data from 7424 meningioma samples as well as targeted sequencing, clinical annotations, and morphology subtyping of 796 samples were examined for differences between females and males regarding mutations, methylation classes, CNVs, and histology.
Results
Meningiomas from females accounted for about 53% of the malignant tumors and present a loss of one X chromosome in 57% of these malignant cases. In the group of benign tumors, females comprised about 75% of the patients. Therein, a loss of one X chromosome was detected in only about 10% of the cases but was associated with a significantly worse progression-free survival.
Conclusions
Although genomic instability is a common feature of malignant meningiomas, particularly loss of the X chromosome in tumors of female patients in otherwise histologically and molecularly low-risk tumors confers higher risk. Hence, the gonosomal copy-number status can be leveraged for increased diagnostic accuracy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.
- Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of Pathology, Leiden University Medical Center, Leiden, Netherlands.
- Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Division of Oncology, Department of Medicine I, Medical University of Vienna, Austria.
ORCID-Profile: Natalie Berghaus, Michael Weller, Wolfgang Wick, Andreas von Deimling, Felix Sahm
Zitieren
APA
Berghaus, N., Hielscher, T., Savran, D., Schrimpf, D., Maas, S. L. N., Preusser, M., Weller, M., Acker, T., Herold-Mende, C., Wick, W., von Deimling, A., & Sahm, F. (2025). Meningiomas: Sex-specific differences and prognostic implications of a chromosome X loss. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae239
Vancouver
Berghaus N, Hielscher T, Savran D, Schrimpf D, Maas SLN, Preusser M, et al. Meningiomas: Sex-specific differences and prognostic implications of a chromosome X loss. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae239
BibTeX
@article{Berghaus2025,
author = {Berghaus, Natalie and Hielscher, Thomas and Savran, Dilan and Schrimpf, Daniel and Maas, Sybren L N and Preusser, Matthias and Weller, Michael and Acker, Till and Herold-Mende, Christel and Wick, Wolfgang and von Deimling, Andreas and Sahm, Felix},
title = {Meningiomas: Sex-specific differences and prognostic implications of a chromosome X loss},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noae239}
}
EUVIMED